MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

计划入组 56 人 · 首次发布于 2014 年 11 月 7 日

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

计划入组 9 人 · 首次发布于 2011 年 1 月 10 日

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

计划入组 28 人 · 首次发布于 2015 年 10 月 30 日

A8-G6

TTA-A8

ALVAC-MAGE-1/MAGE-3 skin cancer vaccine (Sanofi Pasteur)

Maze Therapeutics

Sage Bionetworks

United States

Sage Therapeutics

United States

Author Correction Issued for MAGE-A4/MAGE-A8-Targeted TCR-Based Bispecific T Cell Engager Study

BD Launches Revolutionary FACSDiscover A8 Cell Analyzer with Dual Breakthrough Technologies

Zelluna Achieves Manufacturing Milestone for First-in-Class MAGE-A4 TCR-NK Cell Therapy